With the goal of improving chemotherapy, Jennifer A. Surtees, PhD, associate professor of biochemistry, will study what makes cancer cells sensitive or resistant to different DNA-damaging drugs.
Using mechanical stress, scientists at the University at Buffalo and colleagues have turned normal cells into ‘stem-like’ cells, suggesting a possible safe, new way to produce stem cells.
University at Buffalo research on acetylcholine receptors (AChR) will help pharmacologists better understand how drugs work and could help make “receptor engineering” a reality.
A University at Buffalo biochemist led the first study to identify the liver kinase B1 (LKB1) pathway as a possible therapeutic target for neuropathies, including diabetic neuropathy.
A drug developed by University at Buffalo scientists from a small protein found in spider venom is moving forward as a promising treatment for Duchenne muscular dystrophy, a fatal genetic disease affecting boys.
University at Buffalo researchers have helped discover a sleep-promoting circuit in the brainstem, revealing how we fall into deep sleep — findings that may lead to new therapies for sleep disorders.
Research by David Dietz, PhD, has the potential to identify novel therapies to treat addiction to cocaine and other psychostimulants, for which no effective drug therapy exists.
Wilma A. Hofmann, PhD, assistant professor of physiology and biophysics, will study cellular processes that cause high levels of unsaturated fats to increase the metastatic potential of prostate cancer cells.
University at Buffalo researchers are part of an international team developing a novel imaging technique with nanoparticles suspended in liquid to provide an unparalleled, noninvasive, real-time view of the small intestine.
Anthony L. Auerbach, PhD, professor of physiology and biophysics, will further develop ‘energy maps’ detailing the microscopic changes that occur as neurotransmitters activate protein receptors in a cell’s membrane.
Zhen Yan, PhD, professor of physiology and biophysics, has received $1.6 million to continue her study of human dopamine D4 receptor variants — a type of neurotransmitter receptor in the brain’s prefrontal cortex.
A novel compound severely blunts a host of cocaine addiction behaviors, including relapse behavior, according to a University at Buffalo animal study that holds promise for a groundbreaking treatment.
Using tiny modified liposomes, University at Buffalo researchers are developing a chemotherapy delivery method that could improve cancer treatment, reduce its side effects and boost knowledge about the disease.
Applicants are required to apply to the PhD Program in Biomedical Sciences through Graduate School Application Manager, UB's electronic application system.
